| Authors and year of publication |
Purpose of the study |
Number of patients/procedures used |
Type of study |
Conclusion |
| Andreea et al. 2023 [11] |
Unforeseen advantages or adverse effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors |
N/A |
Review |
The potential harms and benefits of SGLT2 inhibitors as a therapeutic option, indicating the importance of conducting a balanced assessment to determine their overall impact on patient outcomes |
| Chesterman et al. 2020 [12] |
The pros and cons of sodium-glucose cotransporter 2 (SGLT2) inhibitors |
N/A |
Review |
This study highlights the need for careful consideration of both the potential risks and advantages associated with SGLT2 inhibitors to optimize patient outcomes and ensure their safe and effective utilization in clinical practice |
| D’Andrea et al. 2023 [13] |
SGLT2 inhibitors vs DPP-4 inhibitors |
N/A |
Review |
This study highlights the importance of considering individual patient characteristics, including baseline HbA1c levels, when selecting between SGLT2 inhibitors and DPP-4 inhibitors for optimal outcomes in type 2 diabetes management |
| Goit et al. 2019 [14] |
Pharmacological management of patients with type 2 diabetes and cardiovascular disease: a review |
N/A |
Review |
The rising prevalence of type 2 diabetes and its associated cardiovascular (CV) complications pose a significant economic burden. To address this, treatment strategies need to extend beyond glucose control, focusing on event-driven approaches. Fortunately, recent years have witnessed the efficacy of novel anti-diabetic agents in reducing major CV outcomes, heart failure, and end-stage renal disease. This review article presents consensus guidelines for treating type 2 diabetes patients with different categories of CV disease, offering updated information on HbA1c targets and drug selection |
| Han et al. 2021 [15] |
Sodium-glucose cotransporter 2 (SGLT2) inhibitors with dipeptidyl peptidase-4 (DPP-4) inhibitors in elderly individuals with type 2 diabetes |
N/A |
Observational Study |
This study provides valuable evidence for clinical decision-making by demonstrating the effectiveness and safety of sodium-glucose cotransporter-2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP-4) inhibitors in older adults with type 2 diabetes. The findings support SGLT2 inhibitors as a favorable treatment option, offering improved glycemic control and potentially reduced risk of adverse cardiovascular events when compared to DPP-4 inhibitors in this population |
| Joshi et al. 2021 [16] |
Mechanisms of action of sodium-glucose cotransporter 2 (SGLT2) inhibitor therapy in heart failure |
N/A |
Review |
The mechanisms of action of sodium-glucose cotransporter 2 (SGLT2) inhibitors in heart failure are explored, revealing their potential therapeutic benefits in enhancing cardiac function. The findings underscore the significance of SGLT2 inhibitors as a promising treatment option for heart failure, as they operate through novel mechanisms that extend beyond glycemic control and have the potential to positively influence cardiovascular outcomes |
| Kubota et al. 2022 [17] |
Clinical advantages of sodium-glucose cotransporter 2 inhibitors and the cardiovascular effects caused by these drugs |
N/A |
Review |
This article highlights the clinical benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors and explores the underlying mechanisms responsible for their cardiovascular effects. The findings underscore the significant cardiovascular benefits of SGLT2 inhibitors, emphasizing their potential as an effective therapeutic option and contributing to improved patient outcomes in cardiovascular disease management |
| Lopaschuk et al. 2020 [18] |
Mechanisms of sodium glucose cotransporter 2 (SGLT2) inhibitors' cardiovascular advantages |
N/A |
N/A |
This article highlights the potential of SGLT2 inhibitors to improve cardiovascular outcomes by targeting multiple pathways, offering valuable knowledge for advancing clinical practice and further research in this field |
| Mascolo et al. 2022 [19] |
Sodium-glucose cotransporter 2 (SGLT2) inhibitor safety profile |
N/A |
Brief summary |
This article provides a concise overview of the safety profile of sodium-glucose cotransporter 2 (SGLT2) inhibitors, highlighting their potential as a safe treatment option in cardiovascular medicine |
| Salah et al. 2022 [20] |
Sodium-glucose cotransporter 2 and acute heart failure who have type 2 diabetes or not |
N/A |
Systematic Review + Meta-analysis |
The SGLT2 inhibitors show efficacy and safety in patients with acute heart failure, with and without type 2 diabetes |
| Tsai et al. 2022 [21] |
Sodium-glucose cotransporter-2 inhibitors' and cardiovascular and renal systems in people without diabetes |
N/A |
Systematic Review + Meta-analysis |
The SGLT2 inhibitors show cardiovascular and renal efficacy and safety in patients without diabetes |
| Udell et al. 2022 [22] |
For acute myocardial infarction, sodium glucose cotransporter-2 inhibition is used |
N/A |
Review |
This article highlights the potential benefits of sodium-glucose cotransporter-2 (SGLT2) inhibition as a therapeutic strategy for acute myocardial infarction, suggesting its promising role in improving outcomes for patients |
| Yang et al. 2020 [23] |
Inhibitors of sodium-glucose cotransporter-2 and their effects on the heart |
N/A |
Review |
This article provides an overview of the cardiovascular effects and underlying mechanisms of sodium-glucose cotransporter-2 (SGLT2) inhibitors, shedding light on their potential therapeutic impact in managing chronic diseases |
| Yang et al. 2019 [24] |
Sodium-glucose cotransporter 2 inhibitors' effectiveness and security in treating type 2 diabetes in East Asians |
N/A |
Meta-analysis |
The SGLT2 inhibitors show efficacy and safety in East Asians with type 2 diabetes |
| Zhang et al. 2018 [25] |
Inhibitors of sodium-glucose cotransporter 2's cardiovascular safety, long-term no cardiovascular safety, and effectiveness in people with type 2 diabetes |
N/A |
Systematic Review + Meta-analysis |
The SGLT2 inhibitors show cardiovascular safety, long-term non-cardiovascular safety, and efficacy in patients with type 2 diabetes mellitus |
| Pabel et al. 2021 [26] |
Has the riddle around SGLT2 inhibitors and their method of action in heart failure been solved? |
N/A |
Review |
This article explores the mode of action of SGLT2 inhibitors in heart failure and discusses the potential mechanisms behind their beneficial effects. It suggests that while significant progress has been made in understanding their actions, further research is still needed to fully unravel the complexities of their therapeutic impact |
| Gager et al. 2021 [27] |
A meta-analysis of cardiovascular outcomes in individuals treated for heart failure with SGLT2 inhibitors |
N/A |
Meta-analysis |
The SGLT2 inhibitors show favorable cardiovascular outcomes in patients with heart failure |
| Das et al. 2021 [28] |
Heart failure with a lower ejection fraction and SGLT2 inhibitors |
N/A |
Review |
This article focuses on the use of SGLT2 inhibitors in heart failure patients with reduced ejection fraction, highlighting their potential benefits in improving clinical outcomes and reducing mortality. Further studies are warranted to explore their long-term efficacy and safety in this patient population |
| Dyck et al. 2022 [29] |
Evidence for possible off-target effects in the cardiac mechanisms underlying the therapeutic benefits of SGLT2 inhibitors in heart failure |
N/A |
Review |
This article provides insights into the cardiac mechanisms underlying the beneficial effects of SGLT2 inhibitors in heart failure, suggesting potential off-target effects beyond their primary mode of action. These findings emphasize the need for further investigation to fully comprehend the multifaceted mechanisms contributing to the therapeutic benefits of SGLT2 inhibitors in heart failure |
